The primary pain point is data silos. Individual research hospitals and biobanks hold valuable genomic datasets, but HIPAA, GDPR, and donor consent agreements legally prevent sharing this sensitive information. This fragmentation stifles research, limiting statistical power and slowing the discovery of genetic markers for diseases like cancer or rare disorders. The business cost is delayed time-to-market for new therapies and missed competitive insights, as valuable data remains trapped and underutilized.













